Egetis Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

Egetis Therapeutics (STO:EGTX) Full Year 2023 Results

Key Financial Results

• Revenue: kr57.6m (up 155% from FY 2022).
• Net loss: kr326.9m (loss widened by 69% from FY 2022).
• kr1.27 loss per share (further deteriorated from kr1.00 loss in FY 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Egetis Therapeutics Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 63%. Earnings per share (EPS) missed analyst estimates by 6.6%.

Looking ahead, revenue is forecast to grow 67% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Sweden.

Performance of the Swedish Biotechs industry.

The company's shares are up 4.8% from a week ago.

Risk Analysis

Be aware that Egetis Therapeutics is showing 2 warning signs in our investment analysis and 1 of those doesn't sit too well with us...

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.